Aptar Digital Health, part of Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a strategic partnership with the Chiesi Group, the international research-focused biopharmaceutical and healthcare group, to bring to market a disease management platform for asthma and chronic obstructive pulmonary disease (COPD). Aptar Digital Health is a division of Aptar Pharma, part of Aptar (NYSE:ATR).
The partnership will leverage Aptar’s recently announced Disease Management Platform that is designed to empower patients to better understand and take control of their disease, provide healthcare professionals with data-driven insights to better manage their patients and build evidence for emerging reimbursement arrangements in the field of digital health for asthma and COPD. The platform offers a comprehensive set of services and solutions aimed at bringing together both the pharmacological and behavioral aspects of managing respiratory diseases, such as adherence monitoring, lung function assessment, reporting symptoms, identifying disease triggers and communication with care teams and health coaches. The partnership initially focuses on Europe, with potential future expansions to other geographies.
Respiratory illnesses such as asthma and COPD represent an enormous burden on healthcare systems in Europe. It is estimated that 6% of the current European population is living with asthma, and over 60 million people aged between 30 and 79 years old are thought to be suffering from COPD. The greatest economic burden of respiratory diseases on health services in Europe is due to the chronic problems of COPD and asthma, which currently stands at about €40 billion.
“Aptar Digital Health, with its technology and pharma expertise, is uniquely positioned to offer such a complete solution – from software to connected devices to patient monitoring and data analysis,” said Gael Touya, President of Aptar Pharma. “We are delighted to partner with Chiesi and excited to be able to actively contribute to expanding patient access to holistic, end-to-end services that will durably enhance their respiratory disease management.”
“This collaboration reflects our commitment to providing best-in-class level of care for people living with COPD and asthma, going beyond treatments alone and focusing on the patient experience,” commented Alessandro Chiesi, Chief Commercial Officer of the Chiesi Group. “We are looking forward to leveraging Aptar Digital Health’s deep expertise in disease management, with the goal to improve the quality of life of patients afflicted with respiratory diseases and procure tools that contribute to the sustainability of healthcare services for chronic conditions.”
Added Sai Shankar, President, Aptar Digital Health, “This collaboration leads the way for our recently launched Disease Management Platform offering and reinforces our conviction that end-to-end solutions designed to improve patient care are the future of healthcare.”
Download full Press Release.
Reference Sources:
https://ec.europa.eu/eurostat/web/products-eurostat-news/-/edn-20210924-1
https://www.england.nhs.uk/ourwork/clinical-policy/respiratory-disease/
https://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/
The cost of respiratory disease – ERS (erswhitebook.org)
